Related Experiment Video
Updated: Jun 5, 2026
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy:
Yutong Wu1, Yue Zhou1, Wanshuang Yin1
1Department of Neurology, Second Affiliated Hospital of Army Medical University, Chongqing, China.
Objective:
To analyze and compare the efficacy of ripertamab, rituximab, and efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on treatment response rates, relapse rates, drug safety, long-term clinical outcomes, and biomarker characteristics.
Methods:
A multicenter, retrospective cohort study was conducted, patients diagnosed with CIDP were enrolled if they had received at least one course of ripertamab, rituximab, or efgartigimod. A total of 60 patients were included. At baseline and at each follow-up time point, the clinical results were evaluated by disease-specific grading scale, and the correlations between biomarker spectrum and disease activity was explored.
Results:
A total of 60 patients were enrolled, with 27, 19, and 14 patients assigned to the rituximab, ripertamab, and efgartigimod groups, At the 3-month post-treatment assessment, the mean of the INCAT score decreased by 0.519 points in the rituximab group, 1.737 points in the ripertamab group, and 0.214 points in the efgartigimod group as compared to baseline.
Conclusion:
Ripertamab demonstrated efficacy in managing short-term disease outcomes in patients with CIDP, with no significant difference observed when compared to rituximab or efgartigimod. These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.
